Europe Overactive Bladder Treatment Market Size, Share, Trends & Growth Forecast Report By Treatment, Disease and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, From (2025 to 2033)
The size of the Europe overactive bladder treatment market was valued at USD 1.02 billion in 2024. This market is expected to grow at a CAGR of 3.2% from 2025 to 2033 and be worth USD 1.35 billion by 2033 from USD 1.05 billion in 2025.
The growing patient population suffering from the overactive bladder in the European region propels the European market growth. An estimated 17% of the European population aged above 40 years of age are suffering from overactive bladder. Women are more affected by this disorder. Mostly, older people suffer from enlarged prostate and diabetes, resulting in bladder function issues. Some physical movements or activities that put pressure on the urinary bladder are coughing, sneezing, laughing, and exercising. Therefore, the population prefers overactive bladder treatment through oral capsules and injections.
The increasing development of novel drugs and treatments for overactive bladder disorders is another factor boosting the European overactive bladder treatment market. The governments of European countries have conducted numerous surveys on the population suffering from overactive bladder disorder and their treatment. The data populated has been handed over to the researchers to focus on developing new drugs that can effectively help reduce urinary infections and urgent urine problems.
In addition, the growing investments from European governments and the presence of favorable reimbursement policies in the European region are expected to fuel the growth rate of the European market. The rising prevalence of Parkinson's disease in the European region led to the development of overactive bladder disorder, which is estimated to propel the growth of the overactive bladder treatment market in Europe. Parkinson's disease is a type of brain disorder that results in uncontrolled movements such as shaking, stiffness, and urgency during urination. The nervous system controls all the nerves in the body. As a result, these people also choose an overactive bladder treatment to stop the unnecessary urinary flow.
However, side effects associated with overactive bladder drugs as part of the treatment procedure are one of the major factors hampering the regional market growth. Common side effects are dry mouth, dry eyes, constipation, and others. In addition, poor drug awareness levels are another factor hindering market growth. Furthermore, the unavailability of the drugs in every medical store, negligence of the disorder among the population, and a long time for the approval of the drugs are the other factors that impede the market growth.
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| Segments Covered | By Treatment, Disease, and Region. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and Rest of Europe |
| Market Leaders Profiled | Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International |
The Europe overactive bladder treatment market had a substantial share of the worldwide market in 2022 and is estimated to witness a healthy CAGR during the forecast period, owing to the increasing awareness of available treatment options and increasing healthcare expenditure. In addition, an increasing number of product approvals is expected to aid the regional market growth during the forecast period. For instance, Dysport gained approval from the European government for managing urine incontinence in adults suffering from neurogenic detrusor overactivity. This is released in the form of an injection manufactured by Ipsen.
The UK market is anticipated to capture the largest share of the Europe overactive bladder treatment market during the forecast period. An estimated 12% of the total adult population in the UK suffers from overactive bladder disorder. Some of the causes of overactive bladder are weak pelvic muscles, nerve damage due to stroke, and side effects of medication, alcohol, and smoking. One in six women in the United Kingdom suffers from an overactive bladder disorder.
The German market in the European region is projected to witness a healthy CAGR in the coming years, owing to the increasing number of clinical trial centers in Germany. In addition, owing to the clinical center's presence, many local researchers are focusing on developing oral drugs for all age groups to relieve the overactive bladder disorder issue at an affordable price for all types of people. In addition, several measures have been taken by the government to approve the medicine for the population's safety.
Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V., Sanofi, Aurobindo Pharma Ltd, and Endo International are some of the noteworthy companies in the European overactive bladder treatment market.
This Europe consumer healthcare market research report is segmented and sub-segmented into the following categories.
By Treatment
By Disease
By Country
Frequently Asked Questions
The Europe overactive bladder treatment market is driven by a growing patient population, especially adults over 40, increasing prevalence of related conditions like Parkinson’s disease and diabetes, and rising development of novel drugs and treatments supported by government investments and favorable reimbursement policies.
Challenges include side effects from overactive bladder drugs such as dry mouth and constipation, poor drug awareness among patients, unavailability of medications in all medical stores, negligence toward the disorder, and lengthy drug approval processes that hinder market growth.
Opportunities lie in increasing awareness of treatment options, growing healthcare expenditure, new product approvals like Dysport for neurogenic detrusor overactivity, and expanding clinical trials and research efforts in countries like Germany and the UK to develop affordable and effective therapies.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region